We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ZSAN (MC $30 M) NDA Submission & Partnership expected in Q4

No earlier versions found for this Subject.

Return to ZSAN (MC $30 M) NDA Submission & Partnership expected in Q4
ZSAN= MC $30 M/ NDA Submission + Partnership expected during Q4 -- Company likely has the most effective treatment for migraine a multi billion dollar market .check it out guys could be the potential next 10 Bagger

Partnership which means big Upfront payment and US -NDA submission for their very attractive Drug both expected during Q4 according to their new presentation .Company is brutally underpriced at a ridiculous Market Cap of $30 million = Potential 10 Bagger and more here .GL

Zosano Pharma (ZSAN)

Market Cap $30.6 Million
Cash $17,7 Million
Price: $1.72

Shares Out: 17,7 Million


Zosano: From Phase 3 To Approval Of A Best-In-Class Migraine Treatment